All‐oral daclatasvir plus asunaprevir for chronic hepatitis C virus (HCV) genotype 1b infection: a sub‐analysis in Asian patients from the <scp>HALLMARK DUAL</scp> study
Jia‐Horng Kao(National Taiwan University Hospital), Stephanie Noviello(Novartis (United States)), Eric Hughes(The University of Texas at San Antonio Health Science Center), Rafia Bhore(Bristol-Myers Squibb (Germany)), Jeong Heo(National Cancer Center), Sang Hoon Ahn(Yonsei University), Cheng‐Yuan Peng(China Medical University), A. Torbeyns(Bristol-Myers Squibb (Belgium)), Young‐Suk Lim(Asan Medical Center), Youn‐Jae Lee(Inje University Busan Paik Hospital), Ting‐Tsung Chang(National Cheng Kung University)
Cited by 28
Related Papers
REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19
|New England Journal of Medicine|2020|1.8k
Mitotic and G <sub>2</sub> Checkpoint Control: Regulation of 14-3-3 Protein Binding by Phosphorylation of Cdc25C on Serine-216
|Science|1997|1.3k
Brivanib Versus Sorafenib As First-Line Therapy in Patients With Unresectable, Advanced Hepatocellular Carcinoma: Results From the Randomized Phase III BRISK-FL Study
|Journal of Clinical Oncology|2013|775
All‐oral 12‐week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY‐3 phase III study
|Hepatology|2015|689
SIRveNIB: Selective Internal Radiation Therapy Versus Sorafenib in Asia-Pacific Patients With Hepatocellular Carcinoma
|Journal of Clinical Oncology|2018|653